Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
Clinical trial NCT04123366 · COMPLETED
Trial details
- NCT number
- NCT04123366
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-18
- Primary completion
- 2026-06-08
- Enrollment
- 333
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.